FDA issues Complete Response Letter for CL 108 (hydrocodone, acetaminophen, promethazine), an investigational treatment for the management of pain.-Charleston Labs + Daiichi Sankyo.
Charleston Laboratories, Inc., and Daiichi Sankyo, Inc., confirmed that the FDA has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for CL 108 (hydrocodone, acetaminophen, promethazine), an investigational treatment for the management of pain severe enough to require an opioid analgesic while preventing or reducing the associated opioid-induced nausea and vomiting when alternative treatments for pain are inadequate.
The CRL stated that the NDA in its present form was not approved and provided guidance on information needed to resolve matters identified. Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. intend to work closely with the FDA to address the points raised in this action.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins